Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 351

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 351
---
Commercial milestones$59,000 $(7,092)$51,908 12.6Developed technology226,620 (29,248)197,372 10.7Assembled workforce970 (431)539 1.7Total intangible assets$286,590 $(36,771)$249,819 11.1Amortization expense was $5.9 million and $11.9 million for the three and six months ended June 30, 2025, respectively, and $5.7 million and $11.2 million for the three and six months ended June 30, 2024, respectively. Amortization expense was included in cost of sales in the accompanying unaudited condensed consolidated statements of operations. The following table summarizes the estimated future amortization expense associated with the Company’s intangible assets as of June 30, 2025 (in thousands): Amount2025 (remaining six months)11,949 202623,791 202723,575 202823,575 202923,575 Thereafter131,405  $237,870 

13

Accrued ExpensesAccrued expenses consist of the following (in thousands): June 30,2025December 31,2024Accrued sales deductions$50,787 $37,361 Accrued compensation and related benefits26,838 32,248 Accrued professional service fees14,023 12,545 Accrued contract manufacturing and non-clinical costs6,540 7,555 Accrued royalties payable11,255 9,361 Accrued clinical trials11,419 7,148 Accrued interest2,108 2,108 Accrued loss on firm purchase commitments2,088 1,898 Operating lease liabilities, current2,081 1,709 Total accrued expenses and other current liabilities$127,139 $111,933 Other liabilitiesOther liabilities consist of the following (in thousands): June 30,2025December 31,2024Noncurrent accrued sales deductions and other$5,106 $— Noncurrent accrued loss on firm purchase commitments3,948 2,509 Total other liabilities$9,054 $2,509 

6. Asset Acquisitions

License Agreement with Enthorin Therapeutics, LLCIn October 2024, the Company entered into a license agreement with